INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Oct. 12, 2018	Aug. 20, 2018	Dec. 31, 2020	Dec. 31, 2019
Naltrexone Implant Formulation [Member] \| Australia from Trinity Compound Solutions [Member]
Cash paid for acquisition		$ 10,000
Aggregate purchase price, Shares		20,000
Aggregate purchase price, value		$ 236,000
Patent acquired	$ 15,200
Patents [Member]
Amortization expense			$ 1,172	$ 1,464
Estimated useful lives	13 years
Accumulated amortization			2,636	1,464
Intellectual Property [Member]
Amortization expense			47,160	$ 11,990
Estimated useful lives				5 years
Accumulated amortization			$ 59,150	$ 11,990